Literature DB >> 30996133

Human antibody response to Zika targets type-specific quaternary structure epitopes.

Matthew H Collins1,2, Huy A Tu3,4, Ciara Gimblet-Ochieng5, Guei-Jiun Alice Liou5, Ramesh S Jadi5, Stefan W Metz5, Ashlie Thomas5, Benjamin D McElvany4, Edgar Davidson6, Benjamin J Doranz6, Yaoska Reyes7, Natalie M Bowman2, Sylvia Becker-Dreps8, Filemón Bucardo7, Helen M Lazear5, Sean A Diehl3,4, Aravinda M de Silva5.   

Abstract

The recent Zika virus (ZIKV) epidemic in the Americas has revealed rare but serious manifestations of infection. ZIKV has emerged in regions endemic for dengue virus (DENV), a closely related mosquito-borne flavivirus. Cross-reactive antibodies confound studies of ZIKV epidemiology and pathogenesis. The immune responses to ZIKV may be different in people, depending on their DENV immune status. Here, we focus on the human B cell and antibody response to ZIKV as a primary flavivirus infection to define the properties of neutralizing and protective antibodies generated in the absence of preexisting immunity to DENV. The plasma antibody and memory B cell response is highly ZIKV type-specific, and ZIKV-neutralizing antibodies mainly target quaternary structure epitopes on the viral envelope. To map viral epitopes targeted by protective antibodies, we isolated 2 type-specific monoclonal antibodies (mAbs) from a ZIKV case. Both mAbs were strongly neutralizing in vitro and protective in vivo. The mAbs recognize distinct epitopes centered on domains I and II of the envelope protein. We also demonstrate that the epitopes of these mAbs define antigenic regions commonly targeted by plasma antibodies in individuals from endemic and nonendemic regions who have recovered from ZIKV infections.

Entities:  

Keywords:  Adaptive immunity; B cells; Immunoglobulins; Immunology; Virology

Mesh:

Substances:

Year:  2019        PMID: 30996133      PMCID: PMC6538335          DOI: 10.1172/jci.insight.124588

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  84 in total

1.  B-cell responses during primary and secondary dengue virus infections in humans.

Authors:  Anuja Mathew; Kim West; Siripen Kalayanarooj; Robert V Gibbons; Anon Srikiatkhachorn; Sharone Green; Daniel Libraty; Smita Jaiswal; Alan L Rothman
Journal:  J Infect Dis       Date:  2011-09-19       Impact factor: 5.226

2.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Authors:  Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

Review 3.  Vaccination Against Dengue: Challenges and Current Developments.

Authors:  Bruno Guy; Jean Lang; Melanie Saville; Nicholas Jackson
Journal:  Annu Rev Med       Date:  2015-10-23       Impact factor: 13.739

4.  VIROLOGY. Diagnostics for Zika virus on the horizon.

Authors:  Scott D Speer; Theodore C Pierson
Journal:  Science       Date:  2016-08-19       Impact factor: 47.728

Review 5.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

Review 6.  Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere.

Authors:  Helen M Lazear; Michael S Diamond
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

7.  Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.

Authors:  Usha K Nivarthi; Nurgun Kose; Gopal Sapparapu; Douglas Widman; Emily Gallichotte; Jennifer M Pfaff; Benjamin J Doranz; Daniela Weiskopf; Alessandro Sette; Anna P Durbin; Steve S Whitehead; Ralph Baric; James E Crowe; Aravinda M de Silva
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

8.  STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation.

Authors:  Sean A Diehl; Heike Schmidlin; Maho Nagasawa; Simon D van Haren; Mark J Kwakkenbos; Etsuko Yasuda; Tim Beaumont; Ferenc A Scheeren; Hergen Spits
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

9.  A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins.

Authors:  Guntur Fibriansah; Joanne L Tan; Scott A Smith; Ruklanthi de Alwis; Thiam-Seng Ng; Victor A Kostyuchenko; Ramesh S Jadi; Petra Kukkaro; Aravinda M de Silva; James E Crowe; Shee-Mei Lok
Journal:  Nat Commun       Date:  2015-02-20       Impact factor: 14.919

10.  Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques.

Authors:  Jeffy George; William G Valiant; Mary J Mattapallil; Michelle Walker; Yan-Jang S Huang; Dana L Vanlandingham; John Misamore; Jack Greenhouse; Deborah E Weiss; Daniela Verthelyi; Stephen Higgs; Hanne Andersen; Mark G Lewis; Joseph J Mattapallil
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

View more
  14 in total

1.  Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.

Authors:  Laura A VanBlargan; Pavle S Milutinovic; Leslie Goo; Christina R DeMaso; Anna P Durbin; Stephen S Whitehead; Theodore C Pierson; Kimberly A Dowd
Journal:  J Virol       Date:  2021-09-22       Impact factor: 5.103

2.  Molecular Communications in Viral Infections Research: Modeling, Experimental Data, and Future Directions.

Authors:  Michael Taynnan Barros; Mladen Veletic; Masamitsu Kanada; Massimiliano Pierobon; Seppo Vainio; Ilangko Balasingham; Sasitharan Balasubramaniam
Journal:  IEEE Trans Mol Biol Multiscale Commun       Date:  2021-04-15

Review 3.  Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies.

Authors:  Nathaniel L Miller; Rahul Raman; Thomas Clark; Ram Sasisekharan
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

4.  Human Monoclonal Antibody Derived from Transchromosomic Cattle Neutralizes Multiple H1 Clades of Influenza A Virus by Recognizing a Novel Conformational Epitope in the Hemagglutinin Head Domain.

Authors:  Rongyuan Gao; Chithra C Sreenivasan; Zizhang Sheng; Ben M Hause; Bin Zhou; David E Wentworth; Travis Clement; Dana Rausch; Colin Brunick; Jane Christopher-Hennings; Hua Wu; Christoph L Bausch; Eddie J Sullivan; Adam D Hoppe; Victor C Huber; Dan Wang; Feng Li
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

5.  A Novel Antigenic Site Spanning Domains I and III of the Zika Virus Envelope Glycoprotein Is the Target of Strongly Neutralizing Human Monoclonal Antibodies.

Authors:  Stephen D Graham; Huy A Tu; Benjamin D McElvany; Nancy R Graham; Ariadna Grinyo; Edgar Davidson; Benjamin J Doranz; Sean A Diehl; Aravinda M de Silva; Alena Janda Markmann
Journal:  J Virol       Date:  2021-04-12       Impact factor: 6.549

6.  Oligomeric state of the ZIKV E protein defines protective immune responses.

Authors:  Stefan W Metz; Ashlie Thomas; Alex Brackbill; John Forsberg; Michael J Miley; Cesar A Lopez; Helen M Lazear; Shaomin Tian; Aravinda M de Silva
Journal:  Nat Commun       Date:  2019-10-10       Impact factor: 14.919

7.  Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.

Authors:  Emily N Gallichotte; Ellen F Young; Thomas J Baric; Boyd L Yount; Stefan W Metz; Matthew C Begley; Aravinda M de Silva; Ralph S Baric
Journal:  mBio       Date:  2019-09-17       Impact factor: 7.867

Review 8.  Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade.

Authors:  Jin Sun; Senyan Du; Zhihang Zheng; Gong Cheng; Xia Jin
Journal:  Front Microbiol       Date:  2020-03-20       Impact factor: 5.640

Review 9.  Cross-Reactive Immunity Among Flaviviruses.

Authors:  Abhay P S Rathore; Ashley L St John
Journal:  Front Immunol       Date:  2020-02-26       Impact factor: 7.561

10.  Antigenicity, stability, and reproducibility of Zika reporter virus particles for long-term applications.

Authors:  J Charles Whitbeck; Anu Thomas; Kathryn Kadash-Edmondson; Ariadna Grinyo-Escuer; Lewis J Stafford; Celine Cheng; Grant C Liao; Frederick W Holtsberg; M Javad Aman; Graham Simmons; Edgar Davidson; Benjamin J Doranz
Journal:  PLoS Negl Trop Dis       Date:  2020-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.